Gaucher Disease Treatment Market Size, Share and Forecast 2019-2025
The global Gaucher disease treatment market is anticipated to grow at a considerable CAGR of around 3% during the forecast period. Gaucher disease is a type of genetic disease caused by mutation of cells that leads to one of the enzymes in the body not working properly. The body constantly recycles itself as old cells die and new cells are made There is a long list of enzymes that are responsible for the recycling dead cells, one of which when it's not working properly leads to Gaucher disease. Gaucher disease has a lot of different symptoms out of which the most common is an enlarged liver and spleen. Currently, quite a lot of research is going on in the field regarding the treatment of Gaucher disease, which in turn, fuelling the growth of the Gaucher disease treatment market.
To Request a Sample of our Report on Gaucher Disease Treatment Market: https://www.omrglobal.com/request-sample/gaucher-disease-treatment-market
However, the SBT causes any adverse
reaction in patients ranging from weight loss, tremor, flatulence, abdominal
pain, dyspepsia, paresthesia, influenza-like symptoms, visual disturbances, and
thrombocytopenia which is lowering the popularity of SBT in the Gaucher disease
market. In addition, the high cost associated with the treatment is limiting
the growth of the global Gaucher disease treatment market. For instance, according
to the National Institute of Health in 2018, the average wholesale prices of
ERTs are $1,903 per vial for imiglucerase (400 units), $1,652 per vial for
velaglucerase (400 units), and $935 per vial for taliglucerase (200 units).
Patients are often administered 60 units/kg every two weeks. As this dosage,
the approximate annual costs for imiglucerase, velaglucerase, and taliglucerase
would be $544,260, $472,475, and $510,510, respectively.
A
full Report of Gaucher Disease Treatment Market is Available at: https://www.omrglobal.com/industry-reports/gaucher-disease-treatment-market
Gaucher
Disease Treatment Market Segmentation
·
Type I
·
Type II
·
Type
III
By Treatment
Type
·
Enzyme
Replacement Therapy (ERT)
·
Substrate
Reduction Treatment (SBT)
Regional
Analysis
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of The World
Company
Profiles
·
AVROBIO,
Inc.
·
Amicus
Therapeutics
·
CENTOGENE
N.V.
·
ERAD
Therapeutics Inc.
·
Genzyme
Corp. (Sanofi Company)
·
Greenovation
Biotech GmbH
·
JCR
Pharmaceuticals Co., Ltd.
·
Johnson
& Johnson (Actelion Pharmaceuticals Ltd.)
·
Lixte
Biotechnology Holdings, Inc.
·
Novartis
International AG
·
ORPHAZYME
A/S
·
Oxyrane
·
Pfizer
Inc.
·
Protalix
BioTherapeutics, Inc.
·
Takeda
Pharmaceutical Co. Ltd.
Reasons to Buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
For More Customized Data, Request for
Report Customization @ https://www.omrglobal.com/report-customization/gaucher-disease-treatment-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
For
More Information, Visit Orion Market Research
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment